Preclinical Pipeline Tradeoff Explorer: Why Science Still Uses Animal Testing

Pre-loaded Case Studies

Active Testing Modalities

In Silico (qSAR/Docking) In Vitro (Organ-on-Chip) In Vivo (Mammalian System)

Live Molecule Clearance & Pathway Simulation

Screening Active: Particle Cascades Live

ADMET Pharmacokinetic Profile Live Metabolite & Clearance Signals

LogP (Lipophilicity)

3.20

Mol Weight

482.5 Da

Chip Clearance

92%

In Vivo Systemic Tox

High (Cardiac)

Throughput / Day

5,000

Animals Required

12 Mice

Pipeline Balance Radar

Systemic Edge Case Inspector

Why Organoids & Microfluidic Chips Miss Cross-Organ Toxicity:

Hepatic Metabolite M2 Cardiac Ion Toxicity

Liver metabolism of CMP-402 creates secondary metabolite M2. Single-organ liver chip passes M2 as non-toxic, but in living mammals, M2 circulating in bloodstream blocks cardiac hERG K+ channels causing fatal arrhythmia.

Hepatic Metabolite M2 Cardiac Ion Toxicity
Systemic Inflammatory Cytokine Storm

Scientific Principles

1. Microfluidic High-Throughput

Human cell Organ-on-a-Chip devices eliminate species-translation errors for single-target cellular pathways, reducing initial animal screening by up to 70%.

2. Multi-Organ Pharmacokinetics

Living mammalian models remain essential for feedback loops involving endocrine systems, immune-vascular dynamics, and secondary circulating metabolites.

3. Terfenadine & Thalomid Cases

Historical disasters like Terfenadine cardiotoxicity and Thalidomide teratogenicity illustrate both species differences and the peril of missing systemic metabolite pathways.